

19<sup>th</sup> Jan 2017

The Manager- Listing  
**BSE Limited**  
Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai - 400001

The Manager- Listing  
**National Stock Exchange of India Limited**  
Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra –Kurla Complex, Bandra (E),  
Mumbai - 400051

Dear Sirs,

**Sub: Granting of authority to Pfizer Limited for certain rights in relation to identified injectable antibiotic products through a delegation of authority.**


We refer to our announcement dated August 24, 2016 intimating the exchanges about the termination of distribution agreement by AstraZeneca UK Limited for Meronem in India, pursuant to a global agreement by AstraZeneca PLC to sell the development and commercialization rights to Pfizer Inc., of its late-stage small molecule antibiotics business.

We also refer to our announcement dated December 1, 2016 intimating the exchanges about the validity period of the distribution agreement being extended upto July 31, 2017, due to delay in the divestment of AstraZeneca's global rights to Meronem.

We now wish to further update that, during the interim period and until the Marketing Authorization transfers are completed, the Company has granted certain authority (through a Delegation of Authority ("DOA")) to Pfizer Limited, which shall include, inter alia, authority to carry out the activities of pricing and reimbursement negotiations, promotional, marketing, tendering, bidding, and distribution in relation to the identified injectable antibiotic products. Pursuant to this, *Meronem IV Injection* which is currently marketed in India by AstraZeneca Pharma India Limited is expected to be transitioned to Pfizer.

Thanking you

For AstraZeneca Pharma India Limited

  
Rajesh Marwaha  
Chief Financial officer & Director